In such a setting, inflammatory cells that were recruited to the tumor site in response to chemokines such as CCL2 and CCL5 continue releasing the inflammatory cytokines TNFα and IL-1β, whose activities further promote the release of the cancer-related chemokines. The gene discussed is CCL2; the disease is cancer.